David C. Myles sold $235k of OLMA
CH. DISCOV. & NON-CLIN DEV OFF at Olema Pharmaceuticals, Inc.. 26,066 shares at an average of $9.01, traded Dec 10, 2024, filed Dec 11, 2024.
Score components
- +15RoleOfficer
- +13Trade size$235k at market
- 0Share of holdings soldSold 4.2% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -40.1%, 3m -46.4%, 6m -51.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-029027, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | AGrant or award Common Stock | +48,750 | $0.00 | $0 | 624,399 | Dec 11, 2024 |
| Dec 10, 2024 | SOpen-market sale Common Stock | -12,452 | $9.38 | $117k | 611,947 | Dec 11, 2024 |
| Dec 11, 2024 | SOpen-market sale Common Stock | -13,314 | $8.66 | $115k | 598,633 | Dec 11, 2024 |
| Dec 11, 2024 | SOpen-market sale Common Stock | -300 | $9.39 | $2,817 | 598,333 | Dec 11, 2024 |
Related signals
Other insiders at Olema Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $82k 2,881 shares | -0% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Ian T Clark director | $7.9M 264,800 shares | -100% | |
| 55Moderate | Olema Pharmaceuticals, Inc. | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | $1.6M 51,000 shares | -8% | |
| 60Notable | Olema Pharmaceuticals, Inc. | Naseem Zojwalla Chief Medical Officer | $7.5M 269,509 shares | -155% | |
| 27Weak | OLMAsell Olema Pharmaceuticals, Inc. | Cyrus Harmon director | $205k 25,000 shares | -3% | |
| 32Weak | OLMAbuy Olema Pharmaceuticals, Inc. | Bain Capital Life Sciences Investors, LLC owner | $1.7M 300,000 shares | +4% | |
| 48Moderate | OLMAbuy Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | - | |
| 75Notable | Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | -100% | |
| 55Moderate | OLMAbuy Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | +99% | |
| 75Notable | Olema Pharmaceuticals, Inc. | G. Walmsley Graham director | $4.7M 700,761 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.